Switching to tenofovir alafenamide in hbv: Nationwide real life data of efficacy and safety from Turkey
Küçük Resim Yok
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir used for the treatment of HIV-1 and HBV infections. It provides more efficient intracellular tenofovir concentrations at a relatively lower dose than provided by tenofovir disoproxil fumarate (TDF). TAF is expected to have efficacy similar to that of TDF with improved safety profile.
Açıklama
Anahtar Kelimeler
Tenofovir alafenamide (TAF), Prodrug, HIV-1, HBV infections
Kaynak
Hepatology
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
74
Sayı
Künye
Tabak, F., Yörük, G., Köksal, İ., Erdem, H., Yıldız, D., İnce, N., ... & Güner, R. (2021). Switching to tenofovir alafenamide in hbv: nationwide real life data of efficacy and safety from Turkey. Hepatology.
